Axumin® (fluciclovine F 18) Imaging Center Directory Registration Form 

To add your imaging center to the Axumin Imaging Center online directory, please complete the form below. Please note, it may take up to 5 business days for your request to be processed.

Have an update to an existing site?
Contact us at info@blueearthdx.com with the current directory listing details, noting the required changes.

Location Details

*Required fields

(Note: This is how your imaging center will be displayed in the directory)
Select type of imaging center:
Has your facility completed Axumin Image Acquisition and Image Interpretation Training?

(Note: Must add http:// or https:// prior to URL)

Contact Information

The following person confirms that they are authorized to submit this request on behalf of the above imaging center.

By submitting this form, I confirm that the above imaging center will be added to the Axumin.com Imaging Center Directory. At any time, the above imaging center can contact Blue Earth Diagnostics at info@blueearthdx.com to be removed from the directory.

INDICATION

Axumin® (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.

IMPORTANT SAFETY INFORMATION

  • Image interpretation errors can occur with Axumin PET imaging. A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence. The performance of Axumin seems to be affected by PSA levels. Axumin uptake may occur with other cancers and benign prostatic hypertrophy in primary prostate cancer. Clinical correlation, which may include histopathological evaluation, is recommended.
  • Hypersensitivity reactions, including anaphylaxis, may occur in patients who receive Axumin. Emergency resuscitation equipment and personnel should be immediately available.
  • Axumin use contributes to a patient’s overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Safe handling practices should be used to minimize radiation exposure to the patient and health care providers.
  • Adverse reactions were reported in ≤1% of subjects during clinical studies with Axumin. The most common adverse reactions were injection site pain, injection site erythema and dysgeusia.

To report suspected adverse reactions to Axumin, call 1-855-AXUMIN1 (1-855-298-6461) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Axumin full Prescribing Information.

You are now leaving Axumin.com. Do you wish to proceed?

Yes, proceed.
No, take me back to Axumin.com